argenx moves toward oMG label after VYVGART beats placebo in ADAPT OCULUS
The Phase 3 trial hit its primary endpoint with a 4.04-point MGII PRO ocular score improvement versus 1.99 for placebo, setting up an sBLA argenx plans to file by the end of Q3 2026.
Executive Summary
- argenx's Phase 3 trial of VYVGART in ocular myasthenia gravis hit its primary endpoint, giving the company positive data to support a label expansion it plans to file with the FDA this quarter.
- No targeted therapy is approved for ocular myasthenia gravis, and this is the first registrational study built specifically for that population, positioning VYVGART to become the first such option if the submission succeeds.
- The filing rests on replicating VYVGART's established generalized myasthenia gravis profile in an adjacent ocular subtype rather than proving a new mechanism, which frames the regulatory bar as consistency rather than novelty.
- Other FcRn-targeted antibodies are advancing in generalized myasthenia gravis and in earlier-stage ocular MG programs, but none has yet reached a completed registrational readout in this specific subtype.
The result
argenx (Euronext & Nasdaq: ARGX) said its Phase 3 ADAPT OCULUS trial (NCT06558279) met its primary endpoint at p=0.012, with adults treated with VYVGART (efgartigimod alfa and hyaluronidase-qvfc) showing a 4.04-point improvement from baseline on the Myasthenia Gravis Impairment Index (MGII) Patient Reported Outcome ocular score at week 4, versus a 1.99-point improvement for placebo. The trial specifically enrolled adults with MGFA Class I disease, meaning ocular muscle weakness only, who were seropositive or seronegative for AChR-Ab and had a baseline MGII (PRO) ocular score of at least 6. argenx said the drug produced a reduction in diplopia and ptosis, the double vision and eyelid drooping that define the disease, and reported no new safety concerns beyond VYVGART's established profile. argenx+1argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular ...Feb 26, 2026A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia GravisNCT06558279
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The stake
"Ocular myasthenia gravis significantly impacts patients' daily lives, affecting vision, independence and the ability to do routine tasks, such as work or drive a car. Yet today, there are no approved targeted medicines for this disease," said Carolina Barnett-Tapia, M.D., Ph.D., Associate Professor of Medicine (Neurology) at the University of Toronto. argenx's chief medical officer, Luc Truyen, M.D., Ph.D., called ADAPT OCULUS "the first registrational study specifically designed to evaluate a targeted therapy for ocular myasthenia gravis". The company said the positive results support a planned supplemental Biologics License Application to the FDA. argenxargenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular ...Feb 26, 2026
Design and dosing
ADAPT OCULUS is a randomized, double-blind, placebo-controlled trial that dosed VYVGART subcutaneously by prefilled syringe. In Part A, participants received four once-weekly injections of efgartigimod PH20 SC or placebo PH20 SC followed by a four-week follow-up; in the Part B open-label extension, participants received two additional cycles of four once-weekly injections. The trial enrolled 141 participants, above the 124 anticipated at registration, and moved from Recruiting to Active, not recruiting status in December 2025, alongside a shift in the registered primary completion date from December 2025 to January 2026. NCT06558279+1A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia GravisNCT06558279argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular ...Feb 26, 2026
Bridging the label
VYVGART already carries an approved profile in generalized myasthenia gravis, so the ocular MG filing tests whether that established mechanism reproduces a benefit in a narrower, ocular-only patient population rather than proving a new therapeutic hypothesis. The result argenx needs to defend at the FDA is replication of the drug's known effect and safety band in this subgroup, not a larger or novel effect. The disclosed p=0.012 primary result and the absence of new safety signals fit that bar. argenxargenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular ...Feb 26, 2026
Competitive frame
FcRn-targeted antibodies are active in the broader myasthenia gravis field: UCB Pharma's rozanolixizumab, Janssen's nipocalimab, and argenx's own generalized MG efgartigimod program all share the FcRn target and monoclonal antibody or protein-therapy modality. In ocular MG specifically, RemeGen's telitacicept (a BAFF/APRIL-targeted therapy, different mechanism) is in Phase 3 with a completion date in December 2026, and UCB has two rozanolixizumab trials in ocular MG advancing toward 2028 and 2031 completions. ADAPT OCULUS is the only completed registrational readout among the ocular MG-specific studies identified in the current field.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.